Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
These are trial averages with structured support, not individual predictions
Severe hyponatremia can progress to seizures or coma
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, was selected as an active-comparator placebo proxy because it was recommended in clinical guidelines as a second-line glucose-lowering therapy, had a similar high cost to the study drugs, showed no effect on cardiovascular outcomes in a large randomized controlled trial and has been validated as a placebo proxy in prior claims-based research 20,41
doi: 10.1172/jci.insight.180114 24 SousaCMBiancurDEWangXHalbrookCJShermanMHZhangLet al
US$ 23.01
US$ 21.01
US$ 23.85
